Genetic abnormalities and challenges in the treatment of acute myeloid Leukemia

Genes and Cancer

Volumn 2, Issue 2, 2011, Pages 95-107

  Kumar, C Chandra ^a  

^a Onconova Therapeutics Inc   (United States)

Author keywords

Acute myeloid leukemia; Genetic abnormalities; New drugs

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMONAFIDE; ANTHRACYCLINE DERIVATIVE; AS 1413; AZACITIDINE; BELINOSTAT; BEVACIZUMAB; CLADRIBINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IDARUBICIN; LENALIDOMIDE; LESTAURTINIB; LINTUZUMAB; LONAFARNIB; MIDOSTAURIN; PANOBINOSTAT; PLACEBO; QUIZARTINIB; RETINOIC ACID; SAPACITABINE; SORAFENIB; SUNITINIB; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME INVERSION 16; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ENVIRONMENTAL EXPOSURE; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; LEUKEMIA REMISSION; LIVER CELL CARCINOMA; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 79960066925     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911408076     Document Type: Review

References (75)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-62.
2. Estey E, Dohner H. Acute myeloid leukemia. Lancet. 2006;368: 1894-907.
3. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol.2009;37:649-58.
4. Leone G, Voso MT, Sica S, Morosetti R, Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma.2001;41:255-76.
5. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta. 1998;1400:233-55.
6. Appelbaum FR. Acute myeloid leukemia in adults. In: Abeloff M, Armitage J, & Kastan M., et al., editors. Clinical oncology, 3rd edition. Philadelphia: Elsevier Science; 2004. p. 2825-48.
7. Pedersen-Bjergaard J, Christiansen DH, Andersen MK, Skovby F. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia. 2002;16:2177-84.
8. Licht JD. Reconstructing a disease: what essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? Cancer Cell. 2006;9:73-4.
9. Szotkowski T, Muzik J, Voglova J, et al. Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999-2009 in 5 hematology intensive care centers in the Czech Republic. Neoplasma. 2010;57(6):578-89.
10. Youn B-S, Mantel C, Broxmeyer HE. Chemokines, chemokine receptors and hematopoiesis. Immunol Rev. 2000;17:150-74.
11. Farag SS, Ruppert AS, Mrozek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:482.
12. Klepin HD, Balducci L. Acute myelogenous leukemia in older adults. Oncologist. 2009;14:222-32.
13. Thomas X. Chemotherapy of acute leukemias in adults. Exp Opin Pharmacother. 2009;10:221-37.
14. National Cancer Institute. Acute myeloid leukemia. Available from: http://www.Seer.cancer.gov/statfacts/html/amyl.htm?statfacts_page=amyl.html&x=15&y=17
15. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin. 2010;60;277-300.
16. West RR, Stafford DA, White AD, Bowen DT, Padua RA. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood. 2000;95:2093-7.
17. Crane MM, Strom SS, Halabi S, et al. Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. Cancer Epidemiol Biomarkers Prev. 1996;5:639-44.
18. Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors: part III-leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res. 1994;137:S68-97.
19. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol.2005;23:6285-95.
20. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French- American-British Cooperative Group. Ann Intern Med. 1985;103:620-5.
21. Harris N, Jaffe E, Diebold J, et al. WHO classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia. J Clin Oncol.1999;17:3835-49.
22. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood.2009;114:937-51.
23. Martens JHA, Stunnenberg HG. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett. 2010;584:2662-9.
24. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-36.
25. Mrózek K, Radmacher MD, Bloomfield CD, Marcucci G. Molecular signatures in acute myeloid leukemia. Curr Opin Hematol. 2009;16:64-9.
26. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-215.
27. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059-64.
28. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7:233-45.
29. Mitelman F, Johansson B, Mertens F, editors. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. 2010. Available from: http://cgap.nci.nih.gov/Chromosomes/Mitelman
30. Cameron ER, Neil JC. The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene. 2004;23:4308-14.
31. de Bruijn MF, Speck NA. Core-binding factors in hematopoiesis and immune function. Oncogene. 2004;23:4238-48.
32. Davis JN, McGhee L, Meyers S. The ETO (MTG8) gene family. Gene. 2003;303:1-10.
33. Meyers S, Lenny N, Hiebert SW. The t (8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol.1995;15:1974-82.
34. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene. 1995;11:2667-74.
35. Lutterbach B, Hiebert SW. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene.2000;245:223-35.
36. Lutterbach B, Hou Y, Durst KL, Hiebert SW. The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc Natl Acad Sci U S A. 1999;96:12822-7.
37. Eguchi M, Eguchi-Ishimae M, Greaves M. Molecular pathogenesis of MLL-associated leukemias. Int J Hematol. 2005;82:9-20.
38. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer.2007;7:823-33.
39. Mrózek K, Dohner H, Bloomfield CD. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol. 2007;14:106-14.
40. Patscka P, Marucci G, Rupport AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8:21): a Cancer and Leukemia Group B study. J Clin Oncol.2006;24:3904-11.
41. Small D. Targeting FLT3 for the treatment of leukemia. Semin Hematol.2008;45:S17-21.
42. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650-65.
43. Tyner JW, Erikson H, Deininger MW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 2009;113:1749-55.
44. Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer. 2004;4:394-400.
45. Ernst P, Wang J, Korsmeyer SJ. The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol. 2002;9:282-7.
46. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6:493-505.
47. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424-33.
48. Goldstone AH, Burnett AK, Avivi I, et al. Secondary AML has a worse outcome than de novo AML even taking into account cytogenetics and age. Blood. 2002;100:88.
49. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63-7.
50. de Lima M, Strom S, Keating M, et al. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood. 1997;90:4719-24.
51. Tallman MS, Gilliland DG, Rowe JM. Drug therapy of acute myeloid leukemia. Blood. 2005;106:1154-63.
52. National Comprehensive Cancer Network. Home page. Available from: www.nccn.org
53. Erba HP. Has there been progress in the treatment of older patients with acute myeloid leukemia? Best Pract Res Clin Haematol. 2010;23:495-501.
54. Schlenk RF, Frohling S, Hartmann F, et al. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of AML HD98-B treatment trial. Leukemia. 2006;20:748-50.
55. Kohrt HE, Coutre SE. Optimizing therapy for acute myeloid leukemia. J Natl Compr Canc Netw. 2008;6:1003-16.
56. Jones CV, Copelan EA. Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation. Future Oncol. 2009;5: 559-68.
57. Deschler B, de Witte T, Mertelsmann R, Lübbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica.2006;91:1513-22.
58. Kell J. Treatment of relapsed acute myeloid leukemia. Rev Recent Clin Trials. 2006;1:103-11.
59. Stapnes C, Gjertsen BG, Reikvam H, Bruserud O. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opin Investig Drugs. 2009;18:433-55.
60. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54-60.
61. Fathi AT, Levis M. Lestaurtinib: a multi-targeted FLT3 inhibitor. Expert Rev Hematol. 2008;2:17-26.
62. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108:3262-70.
63. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114:2984-92.
64. Al-Kali A, Jones D, Cortes J, et al. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with newly diagnosed FLT3-mutant acute myeloid leukemia (AML). Blood. 2009;114. Abstract 2079.
65. Serve H, Wagner R, Sauerland C, et al. Sorafenib in combination with standard induction and consolidation therapy in elderly AML patients: results from a randomized, placebo-controlled phase II trial. Blood.2010;116:333.
66. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2B randomized study of CPX-351 vs. cytarabine (CYT) + daunorubicin (DNR) (7 + 3 regimen) in newly diagnosed AML patients aged 60-75. Program and abstracts from the 52nd American Society of Hematology Annual Meeting and Exposition. Blood. 2010;116:655.
67. Faderl S, Ravandi F, Garcia-Manero G, et al. Frontline therapy for older patients (pts) with acute myeloid leukemia (AML): clofarabine plus low-dose cytarabine induction followed by prolonged consolidation with clofarabine plus low-dose cytarabine alternating with decitabine. Blood. 2010;116:336.
68. Sekeres MA, Gundacker H, Lancet J, et al. A phase II study of lenalidomide for previously untreated deletion (del) 5q acute myeloid leukemia (AML) patients age 60 or older who are not candidates for remission induction chemotherapy (Southwest Oncology Group Study S0605). Blood. 2010;116. Abstract 332.
69. Garcia-Manero G, Tambaro FP, Bekele NB, et al. Final report of a phase II trial of vorinostat, idarubicin and cytarabine in previously untreated acute myelogenous leukemia (AML) or high risk myelodysplastic syndrome (MDS). Blood. 2010;116:2189.
70. Schaefer EW, Loaiza-Bonilla A, Juckett M, et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009;94:1375-82.
71. Erba HP, O'Donnell M, Allen SL, et al. Amonafide L-malate (AS1413) in combination with cytarabine is equally effective in older and younger patients with secondary acute myeloid leukemia (AML): final data from a phase II study. Blood. 2009;114. Abstract 1047.
72. Löwenberg B, Beck J, Graux C, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood. 2010;115:2586-91.
73. Didier C, Cavelier C, Quaranta M, et al. Evaluation of Polo-like kinase 1 inhibition on the G2/M checkpoint in acute myelocytic leukaemia. Eur J Pharmacol. 2008;591:102-5.
74. Silverman LR, Navada SC, Odchimara-Reissig R, et al. Evaluation of ON01910.Na in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsed or refractory to hypomethylating agents: a phase I study. Blood. 2010;116:2944.
75. McCormack E, Bruserud O, Gjertsen BT. Review: genetic models of acute myeloid leukemia. Oncogene. 2008;27:3765-79.